Results 11 to 20 of about 20,698 (251)

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review

Clinical Epidemiology, 2022
Zeyu Xie, Sensen Yang, Weishang Deng, Jinjian Li, Jisheng Chen Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Yang S, Deng W, Li J, Chen J
doaj   +1 more source

Semaglutide and pregnancy

International Journal of Gynecology & Obstetrics, 2023
SynopsisBoth use and cessation of semaglutide constitutes problems prior to and during pregnancy. More problems are expected with increasing use.
Kenneth Skov, Ida Nikoline Mandic, Kathinka Marie Nyborg   +2 more
openaire   +4 more sources

Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis

Frontiers in Pharmacology, 2021
Background: Cardio-renal profiles are available from cardiovascular outcome trials of glucagon-like peptide-1 receptor agonists (GLP-1 RAs).Methods: A comprehensive systematic review of Embase, Medline, Web of Knowledge, and CENTRAL databases was ...
Chuanjun Zhuo, Chuanjun Zhuo, Chuanjun Zhuo, Chuanjun Zhuo, Chongguang Lin, Chunhua Zhou, Xiangyang Gao, Hailin Shao, Tao Fang, Hongjun Tian, Li Ding, Ming Liu   +11 more
doaj   +1 more source

Semaglutide once: semaglutide (1.8%) versus placebo (2.2%)

Researka accepted publication: da7f5bc8-9764-4dfa-963a-fc3eda0b8042 Source submission: 0cf72212-ebe6-4fe6-b108-ed2e08fa3131 semaglutide (1.8%) versus placebo (2.2%); At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%) versus
Dominic Lynch
core   +6 more sources

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

Cardiovascular Diabetology, 2020
Background Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2 diabetes (T2D) available in subcutaneous (s.c.) and oral formulations.
Mansoor Husain, Stephen C. Bain, Anders Gaarsdal Holst, Thomas Mark, Søren Rasmussen, Ildiko Lingvay   +5 more
doaj   +1 more source

Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes

Biomedicines, 2021
Background: An unexpected increase in the rate of severe diabetic retinopathy was observed in the Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN)-6 clinical trial.
Rafael Simó, Patricia Bogdanov, Hugo Ramos, Jordi Huerta, Olga Simó-Servat, Cristina Hernández   +5 more
doaj   +1 more source

Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China

Frontiers in Pharmacology, 2023
Introduction: Oral semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that improves glycated hemoglobin levels and body weight in patients with type 2 diabetes (T2DM).
Zhen Feng, Zhen Feng, Wai Kei Tong, Xinyue Zhang, Zhijia Tang   +4 more
doaj   +1 more source

Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study

Journal of Comparative Effectiveness Research, 2022
What is this summary about? This is a plain language summary of the STEP TEENS research study, which was originally published in the New England Journal of Medicine.
Daniel Weghuber, Klaus Boberg, Dan Hesse, Ole K Jeppesen, Rasmus Sørrig, Aaron S Kelly   +5 more
doaj   +1 more source

Semaglutide as Treatment for Obesity in Adolescents [PDF]

, 2023
Background: Semaglutide was recently approved to treat obesity in adolescents. Main objective: To provide a critical appraisal of semaglutide as anti-obesity agent in adolescents. Methods: Pubmed search up to May 19, 2023.
Mikhail, Nasser, Wali, Soma
core   +1 more source

The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study

Medicines, 2022
Background and Objectives: This study aimed to investigate the changes in obesity severity, glucose metabolism, and body composition in patients with obesity and type 2 diabetes mellitus treated with glucagon-like peptide 1 receptor agonist (GLP1-RA ...
Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata   +7 more
doaj   +1 more source